Journal of Natural Remedies

Open Access Open Access  Restricted Access Subscription Access

Antidiabetic Activity of Vasant Kusumakar Ras in Streptozotocin and High Fat Diet Induced Type 2 Diabetes Mellitus in Sprague Dawley Rats


Affiliations
1 Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
 

Background: VasantKusumakar Ras (VK Ras) is a traditional Ayurvedic preparation used in the treatment of Type-2 diabetes mellitus. Despite its clinical anti-diabetic claims, no pre-clinical attempts were made to rule out its efficacy as an antidiabetic agent. Objectives: The present study was carried out to find the anti-diabetic effect of VK Ras against a High-Fat Diet (HFD), and low-dose streptozotocin (STZ) induced type 2 diabetes and to explore the mode of action of VK Ras. Materials and Methods: Different doses of VK Ras were administered to diabetic rats for 35 days. The biochemical markers analysis, intestinal glucose uptake, and liver glycogen content were estimated at the end of the study and also vital organs were weighed and subjected to histopathological evaluation. Results: VK Ras treatment reduced blood glucose in a dose-dependent manner. The insulin, HbA1C, HOMA-IR, and lipid profiles were improved in VK Ras-treated animals as compared to diabetic control animals. The relative organ weights were changed in diabetic rats, and treatment with VK Ras corrected the organ weights. Intestinal glucose uptake and liver glycogen content were decreased with treatment. Further, the histopathological analysis of the pancreas and other vital organs had shown that dose-dependent restoration of organ function with VK Ras treatment. Conclusions: VK Ras treatment reduces insulin resistance as well as corrects the lipid, hepatic and renal abnormalities that arise from diabetes, these effects may be mediated by interfering with glucose transport from the gut and insulin release from the β pancreatic cells.

Keywords

HbA1C, HFD, HOMA-IR, Insulin, STZ, VK Ras
Font Size

User

Notifications
JOURNAL COVERS
  

  • Oschatz E, Müllner M, Herkner H, Laggner AN. Multiple organ failure and prognosis in adult patients with diabetic ketoacidosis. Wien Klin Wochenschr. 1999; 111(15):590-5. PMID: 10483673.

  • Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015; 6(13):1246-58. https://doi.org/10.4239/wjd.v6.i13.1246 PMid:26468341 PMCid:PMC4600176

  • Chaudhary A, Singh N. Contribution of World Health Organization in the global acceptance of Ayurveda. J Ayurveda Integr Med. 2011; 2(4):179-186. https://doi.org/10.4103/0975-9476.90769 PMid:22253507 PMCid: PMC3255448

  • McWhorter LS. Biological complementary therapies: A Focus on botanical products in diabetes. Diabetes Spectrum. 2001; 14:199-208. https://doi.org/10.2337/diaspect.14.4.199

  • Saxena A, Vikram NK. Role of selected Indian plants in management of type 2 diabetes: a review. Journal of Alternative and Complementary Medicine. 2004; 10:369-78. https://doi.org/10.1089/107555304323062365 PMid:15165418

  • Sarkar PK, Das S, Prajapati PK. Ancient concept of metal pharmacology based on Ayurvedic literature. Anc Sci Life. 2010; 29(4):1-6

  • Tamoli SM, Kohli KR, Kaikini AA, Muke SA, Shaikh AA, Sathaye S. Vasant Kusmakar Ras, an ayurvedic herbo-mineral formulation prevents the development of diabetic retinopathy in rats. J Ayurveda Integr Med. 2020; 11(3):270-276. https://doi.org/10.1016/j.jaim.2020.02.002 PMid:32312587 PMCid:PMC7527844

  • Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 2004; 53(Suppl. 3):S215-S219. https://doi.org/10.2337/diabetes.53.suppl_3. S215 PMid:15561913

  • Kanno A, Asahara SI, Masuda K, Matsuda T, Kimura- Koyanagi M, Seino S, Ogawa W, Kido Y. Compensatory hyperinsulinemia in high-fat diet-induced obese mice is associated with enhanced insulin translation in islets. Biochem Biophys Res Commun. 2015; 458(3):681-686. https://doi.org/10.1016/j.bbrc.2015.02.024 PMid:25686499

  • Brøndum E, Nilsson H, Aalkjaer C. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin- treated diabetic rat models. HormMetab Res. 2005; 37 (Suppl 1):56-60 https://doi.org/10.1055/s-2005-861370 PMid:15918112

  • Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin- treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacological Research. 2005; 52(4):313-320. https://doi.org/10.1016/j.phrs.2005.05.004 PMid:15979893

  • Doluisio JT, Billups NF, Dittert LW, Sugita ET, Swintosky JV. Drug absorption. I. An in-situ rat gut technique yielding realistic absorption rates. J Pharm Sci. 1969; 58(10):1196- 200. https://doi.org/10.1002/jps.2600581006 PMid:5394662

  • Van der vies J. Two methods for the determination of glycogen in liver. Biochem J. 1954; 57(3):410-6. https://doi.org/10.1042/bj0570410 PMid: 13181850 PMCid: PMC1269772

  • Lenzen S. The mechanisms of alloxan- and streptozotocininduced diabetes. Diabetologia. 2008; 51(2):216-26. https:// doi.org/10.1007/s00125-007-0886-7 PMid:18087688

  • Strong JS, Bartholomew BA, Smyth CJ. Immunoresponsiveness of patients with rheumatoid arthritis receiving cyclophosphamide or gold salts. Ann Rheum Dis. 1973; 32(3):233-237. https://doi.org/10.1136/ard.32.3.233 PMid:4715541 PMCid:PMC1006085

  • Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamicchane J, Kanth R, Gayam V. Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Cureus. 2018 2018; 10(11). https://doi.org/10.7759/cureus.3626

  • Ferrannini E, Lanfranchi A, Rohner-Jeanrenaud F, Manfredini G, Van de Werve G. Influence of longterm diabetes on liver glycogen metabolism in the rat. Metabolism. 1990; 39(10):1082-8. https://doi.org/10.1016/0026-0495(90)90170-H PMid:2145494

  • Hussain S, Jamali MC, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clinical Epidemiology and Global Health. 2021; 9:2-6. https://doi.org/10.1016/j. cegh.2020.05.016

  • Harita N, Hayashi T, Sato KK, Nakamura Y, Yoneda T, Endo G, Kambe H. Lower serum creatinine is a new risk factor of type 2 diabetes: The Kansai healthcare study. Diabetes Care. 2009; 32:424-426. https://doi.org/10.2337/dc08-1265 PMid:19074997 PMCid:PMC2646021

  • DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985; 76:149-155. https://doi. org/10.1172/JCI111938 PMid:3894418 PMCid:PMC423730

  • Onuigbo MA, Agbasi N. Diabetic nephropathy and CKD-analysis of individual patient serum creatinine trajectories: A forgotten diagnostic methodology for diabetic CKD prognostication and prediction. J Clin Med. 2015; 4(7):1348-68. https://doi.org/10.3390/jcm4071348 PMid: 26239680 PMCid:PMC4519794

  • Ni Z, Guo L, Liu F, Olatunji OJ, Yin M. Allium tuberosum alleviates diabetic nephropathy by supressing hyperglycemia- induced oxidative stress and inflammation in high fat diet/streptozotocin treated rats. Biomed Pharmacother. 2019; 112. https://doi.org/10.1016/j.biopha.2019.108678 PMid:30784905

  • Gromova LV, Polozov AS, Kornyushin OV, Grefner NM, Dmitrieva YV, Alekseeva AS, Gruzdkov AA. Glucose absorption in the rat small intestine under experimental Type 2 Diabetes Mellitus. J Evol Biochem Physiol. 2019; 55:155-157. https://doi.org/10.1134/S0022093019020091


Abstract Views: 157

PDF Views: 81




  • Antidiabetic Activity of Vasant Kusumakar Ras in Streptozotocin and High Fat Diet Induced Type 2 Diabetes Mellitus in Sprague Dawley Rats

Abstract Views: 157  |  PDF Views: 81

Authors

Sudesh N. Gaidhani
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
Srikanth Ala
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
Viswanth Reddy
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
Y. R. Sanjaya Kumar
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
Shrirang Jamadagni
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
Thamizh Selvam
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India
K. K. Ajeesh Kumar
Pharmacology, National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur - 679531, Kerala, India

Abstract


Background: VasantKusumakar Ras (VK Ras) is a traditional Ayurvedic preparation used in the treatment of Type-2 diabetes mellitus. Despite its clinical anti-diabetic claims, no pre-clinical attempts were made to rule out its efficacy as an antidiabetic agent. Objectives: The present study was carried out to find the anti-diabetic effect of VK Ras against a High-Fat Diet (HFD), and low-dose streptozotocin (STZ) induced type 2 diabetes and to explore the mode of action of VK Ras. Materials and Methods: Different doses of VK Ras were administered to diabetic rats for 35 days. The biochemical markers analysis, intestinal glucose uptake, and liver glycogen content were estimated at the end of the study and also vital organs were weighed and subjected to histopathological evaluation. Results: VK Ras treatment reduced blood glucose in a dose-dependent manner. The insulin, HbA1C, HOMA-IR, and lipid profiles were improved in VK Ras-treated animals as compared to diabetic control animals. The relative organ weights were changed in diabetic rats, and treatment with VK Ras corrected the organ weights. Intestinal glucose uptake and liver glycogen content were decreased with treatment. Further, the histopathological analysis of the pancreas and other vital organs had shown that dose-dependent restoration of organ function with VK Ras treatment. Conclusions: VK Ras treatment reduces insulin resistance as well as corrects the lipid, hepatic and renal abnormalities that arise from diabetes, these effects may be mediated by interfering with glucose transport from the gut and insulin release from the β pancreatic cells.

Keywords


HbA1C, HFD, HOMA-IR, Insulin, STZ, VK Ras

References





DOI: https://doi.org/10.18311/jnr%2F2023%2F32054